Liu

[Jason Smith - 上官杰文 @ShangguanJiewen]

https://t.co/PmgC7J08eR and https://t.co/qKqjtNzeOj are the best.

The Economist, and FT are the worst.

Basically, if you want to read news about China, read Chinese news.

Chinese citizens rate their media as trustworthy, whereas US citizens rate our media as untrustworthy.

Why then, should people in the West trust US legacy news on China, when Chinese news exists? Short answer: they shouldn't.

[Amelia @Amelia181672271]

「日本找美國請求中國對日本出口稀土被拒後，日本商會又來請求中國回復稀土出口和進口日本水產品」

日本不是很厲害嗎？

日本商會首先必須要求日本右翼法西斯，放棄軍國主義野心與干涉中國內政等問題，之後再商討其他事項。

[Liu @MiloMyo]

@nhk_news Cry about it 🤣

[Liu @MiloMyo]

@WarReports24 @shen_shiwei US DOESN’T RUN MASSIVE CYBER CAMPAIGNS? DUDE 🤣 Come on 🤣🤣

[Shen Shiwei 沈诗伟 @shen_shiwei]

This report is a good example of how absurd some #European media coverage of #China has become. The article portrays China as the threat behind the loss of German patents, but the study it cites shows the biggest foreign holders are the US (31.7%), Switzerland (11.1%), and France (7.5%). China ranks only sixth, behind the US, Switzerland, France, Japan, and the UK.
When the data doesn’t fit the narrative, the narrative still wins.

[𝘊𝘰𝘳𝘳𝘪𝘯𝘦 @OopsGuess]

The New York Times is upset because China learned the rules.

When the U.S. and Europe block, seize, unwind, force-sale, sanction, and weaponize “national security” against Chinese investment, it is called protecting the free market.
When China builds legal tools to protect its own capital, technology, data, and companies, suddenly it becomes an “economic fortress.”

Please.

The West taught China this game.
Nexperia.
TikTok.
Panama ports.
Darwin Port.
British Steel.
Semiconductors.
Rare earths.

Chinese money was welcome when it rescued dying assets.
Chinese ownership became dangerous the moment those assets became valuable.

So China built a shield.
Not paranoia.
Pattern recognition.

The era of Chinese capital walking naked into Western legal traps is over.

[高句麗文輸人 @mingyuerugu]

The hairstyles and the Hanfus of Anak Tomb No.3 are the same as Wei,Jin,Southern and Northern Dynasties'.Historical records prove that it is a Chinese tomb.Dongshou is a general from Former Yan,not your ancestor!
#漢服 #Hanfu #동북공정

[桃芷TAOZHI @ruruko_momo]

Traditional Chinese Clothing: Ming-style Hanfu
The Beauty I Paint。
中国传统服饰，我笔下的明制汉服之美。
#汉服 #hanfu #漢服

[Michelle @D162Michele]

The West: We must isolate and decoupled from China!!

How’s that going?🤣🤣

[Life in China with Patrick @Boden2023]

If you want to understand the history of Taiwan and its relationship with China I’d recommend watching this interview with @notXiangyu
Great history lesson!

[Liu @MiloMyo]

@seijichishin Some stupid ppl are crazy that they live with lies. Chinese characters that shown in the video is Grain, it’s grain tank NOT OIL TANK 🤣

[Safari @Safari_liv3]

Koreans, please stop stealing Chinese culture. Once again, you’re appropriating traditional Chinese clothing and falsely claiming it as Korean attire. This behavior is shameful and pathetic. Are you so insecure about Korea’s real history?

[Amelia @Amelia181672271]

作為台灣人，我代表台灣感謝祖國大陸保護台灣領土不被日本和菲律賓侵略。

民進黨不是台灣人，他們是滯台的日本人，他們代表不了台灣。

必要時我願意幫助祖國大陸統一

[Angelo Giuliano 🇨🇭🇮🇹 @angeloinchina]

China Keeps Cancer Drug Rights at Home in Massive $10.5 Billion Pfizer Deal – Explained 🇨🇳

A Chinese biotech powerhouse, Innovent Biologics, has been cooking up next-gen cancer treatments — think antibody-drug conjugates (ADCs), basically smart bombs that deliver chemo straight to tumor cells with way fewer side effects, plus other advanced multispecific antibodies.

They just dropped a monster $10.5 billion global partnership with Pfizer.

How the money flows:
• $650 million upfront cash to Innovent.
• Up to $9.85 billion more in milestone payments if the drugs hit development, approval, and sales targets.
• Plus ongoing royalties on everything Pfizer sells outside China.

Who gets what rights?
• Pfizer gets exclusive rights to develop, manufacture, and sell most of these drugs in the US, Europe, and rest of the world.
• On some programs they’ll co-develop and share profits in the US/EU.
• But here’s the China part: Innovent keeps full rights in Greater China (mainland China, Hong Kong, Macau, and Taiwan). They can develop, produce, price, and sell these exact same drugs in their home market completely on their own, no Pfizer approval needed.

This deal covers multiple early-stage oncology assets, mainly differentiated ADCs and next-gen antibody therapies. Innovent handles early development, Pfizer takes the global later stages and commercialization outside China.

Why this matters (classic China biotech playbook):
Chinese companies create innovative drugs in a fast, lower-cost environment. They license the global rights (ex-China) to Big Pharma giants like Pfizer for massive cash and worldwide reach. At the same time, they never surrender control at home.
Result?
• China exports the innovation and banks billions.
• Chinese patients can get faster, potentially much more affordable access.
• Expected reality: Pfizer is likely to jack up prices significantly when these drugs are commercialized in the West (standard Big Pharma pricing in high-margin markets with less government control), while Innovent will keep them much cheaper in China thanks to domestic pricing pressures and volume strategy.
• Domestic firms keep building R&D, manufacturing, and commercial muscle.
• China strengthens its grip on the world’s second-largest pharma market.
Win-win, Chinese style: Out-license globally, dominate locally. Pfizer gets fresh oncology firepower for its international pipeline (at premium Western prices). Innovent gets validation and capital to keep scaling while protecting affordable access back home.

This is exactly how China’s biotech sector is playing the long game — smart IP strategy, home-market protection, and global cash flow all at once.

[Mysteries @LOTM_WORLD]

🚨| Lord of Mysteries is officially confirmed to have 3 special episodes.

- Release Date: June 20

[HobbebebeGA @usa_hobby01]

中国汉服店，洛丽塔店，早就成了日本画师的素材库。
中国古建筑扫描图，中国结笔刷甚至成了韩漫画师公用素材网站的素材包。

如果是反过来，国内舆论早就炸锅了，但现在是中国文化被偷，中国设计被未授权使用，国内的左比和萌二们开始大谈大度😅

[明月 @KKKopycat]

@huohua2645 @dailykusuriya @NaMelanza 🤔倭國畫師什麼時候標註原作者？薬屋のひとりごと在2024年4月抄襲了中國漢服品牌花至原創漢服的商品，2024年之前就有不少中國留學生在畢業典禮穿這款漢服https://t.co/iCD0QhGT5R

[HobbebebeGA @usa_hobby01]

问题在于药屋少女把中華风动漫说成“东洋风”。
本就有大量中国内容被当成日本的（比如把汉服当成和服），这个作品里日本文化的含量可能只有日本的配音员。
然而作者的态度，是进一步强调这部动漫里那少得可怜的“日本文化”，客观上促进大量日本右翼网民每天宣传中国古文化与现代中国无关的论调。